WO2011121607A3 - Rasagiline and its pharmaceutically acceptable salts - Google Patents

Rasagiline and its pharmaceutically acceptable salts Download PDF

Info

Publication number
WO2011121607A3
WO2011121607A3 PCT/IN2011/000213 IN2011000213W WO2011121607A3 WO 2011121607 A3 WO2011121607 A3 WO 2011121607A3 IN 2011000213 W IN2011000213 W IN 2011000213W WO 2011121607 A3 WO2011121607 A3 WO 2011121607A3
Authority
WO
WIPO (PCT)
Prior art keywords
rasagiline
pharmaceutically acceptable
acceptable salts
relates
compositions
Prior art date
Application number
PCT/IN2011/000213
Other languages
French (fr)
Other versions
WO2011121607A2 (en
Inventor
Shriprakash Dhar Dwivedi
Ashok Prasad
Mayur Ramnikbhai Patel
Original Assignee
Cadila Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Limited filed Critical Cadila Healthcare Limited
Publication of WO2011121607A2 publication Critical patent/WO2011121607A2/en
Publication of WO2011121607A3 publication Critical patent/WO2011121607A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

The present invention relates to rasagiline (I) and its pharmaceutically acceptable salts. The invention also relates to improved processes for the preparation of rasagiline and its pharmaceutically acceptable salts. The invention also relates to pharmaceutical compositions that include the pharmaceutically acceptable salts of rasagiline and use of the compositions for treating the signs and symptoms of idiopathic Parkinson's disease as initial monotherapy and as adjunct therapy to levodopa.
PCT/IN2011/000213 2010-03-29 2011-03-29 Rasagiline and its pharmaceutically acceptable salts WO2011121607A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN949MU2010 2010-03-29
IN949/MUM/2010 2010-03-29

Publications (2)

Publication Number Publication Date
WO2011121607A2 WO2011121607A2 (en) 2011-10-06
WO2011121607A3 true WO2011121607A3 (en) 2011-12-15

Family

ID=44211868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000213 WO2011121607A2 (en) 2010-03-29 2011-03-29 Rasagiline and its pharmaceutically acceptable salts

Country Status (1)

Country Link
WO (1) WO2011121607A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8741962B2 (en) * 2009-11-26 2014-06-03 Usv Limited Process for preparation of Rasagiline and salts thereof
HU231054B1 (en) * 2010-11-18 2020-04-28 Egis Gyógyszergyár Nyrt. Novel salts suitable for the preparation of pharmaceutical compositions
EP2705021A2 (en) 2011-05-04 2014-03-12 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
DE102012000786A1 (en) 2012-01-18 2013-07-18 Stada Arzneimittel Ag Process for the preparation of a solid pharmaceutical composition containing the active substance rasagiline
IN2013MU01782A (en) * 2013-05-20 2015-06-26 Cadila Healthcare Ltd

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011016A1 (en) * 1993-10-18 1995-04-27 Teva Pharmaceutical Industries Ltd. R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof
EP1892233A1 (en) * 2006-08-18 2008-02-27 Ratiopharm GmbH New salts of the active component rasagiline
WO2010007181A2 (en) * 2008-07-18 2010-01-21 Medichem, S.A. New salt forms of an aminoindan derivative
EP2181980A1 (en) * 2008-10-28 2010-05-05 Chemo Ibérica, S.A. A process for the preparation of (R)-1-aminoindanes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
MX2009006251A (en) 2006-12-14 2009-10-12 Teva Pharma Crystalline solid rasagiline base.
EP1987816A1 (en) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate of a rasagiline salt with a water-soluble inactive ingredient
US20110105788A1 (en) 2008-03-28 2011-05-05 Medichem, S.A. Polymorphic Form of an Aminoindan Mesylate Derivative
AT507047A1 (en) 2008-06-30 2010-01-15 Uv & P Umweltman Verfahrenstec METHOD FOR STACKING BALE-TREATED CONTAINERS
EP2328861A2 (en) 2008-07-11 2011-06-08 Synthon BV Polymorphs of rasagiline hydrochloride
JP2012532843A (en) 2009-07-09 2012-12-20 ラティオファーム ゲーエムベーハー Rasagiline salt and preparation thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011016A1 (en) * 1993-10-18 1995-04-27 Teva Pharmaceutical Industries Ltd. R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof
EP1892233A1 (en) * 2006-08-18 2008-02-27 Ratiopharm GmbH New salts of the active component rasagiline
WO2010007181A2 (en) * 2008-07-18 2010-01-21 Medichem, S.A. New salt forms of an aminoindan derivative
EP2181980A1 (en) * 2008-10-28 2010-05-05 Chemo Ibérica, S.A. A process for the preparation of (R)-1-aminoindanes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRÜNING J. ET AL.: "Rasagiline ethanedisulfonate: an inhibitor for monoamine oxygenase B (MAOB) - Supplementary material DN3098", 12 October 2011 (2011-10-12), XP002661176, Retrieved from the Internet <URL:http://dx.doi.org/10.1107/S0108270108032526/dn3098sup3.pdf> [retrieved on 2008] *
CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954, ISSN: 0340-1022, ISBN: 978-3-540-36760-4, DOI: DOI:10.1007/3-540-69178-2_5 *
JÜRGEN BRÜNING ET AL: "Rasagiline ethanedisulfonate: an inhibitor for monoamine oxygenase B (MAO B )", ACTA CRYSTALLOGRAPHICA SECTION C CRYSTAL STRUCTURE COMMUNICATIONS, vol. 64, no. 11, 25 October 2008 (2008-10-25), pages O613 - O615, XP055002171, ISSN: 0108-2701, DOI: 10.1107/S0108270108032526 *
STAHL PETER HEINRICH ET AL: "Handbook of Pharmaceutical salts, Table 1. Acids: Alphabetical Order", 1 January 2002, HANDBOOK OF PHARMACEUTICAL SALTS : PROPERTIES, SELECTION, AND USE, ZÜRICH : VERL. HELVETICA CHIMICA ACTA ; WEINHEIM [U.A.] : WILEY-VCH, DE, PAGE(S) 334 - 335, ISBN: 978-3-906390-26-0, XP002585571 *

Also Published As

Publication number Publication date
WO2011121607A2 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
CA2871471C (en) Dna-pk inhibitors
WO2013173129A3 (en) Treatment of amd using aav sflt-1
MY178634A (en) Topical formulation for a jak inhibitor
WO2012080727A3 (en) Casein kinase 1delta (ck1delta) inhibitors
MX338712B (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof.
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson&#39;s disease
WO2013188792A3 (en) Neuroactive steroids, compositions, and uses thereof
EP3626253A3 (en) Stable formulations of linaclotide
WO2011107653A3 (en) Use of levodopa, carbidopa and entacapone for treating parkinson&#39;s disease
MY156434A (en) Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs
NZ703341A (en) Compositions comprising apomorphine and organic acids and uses thereof
UA109661C2 (en) Pharmaceutical compositions comprising co-crystals of tramadol and celecoxib
NZ759512A (en) Delayed release compositions of linaclotide
WO2012048129A3 (en) Inhibitors of polo-like kinase
WO2014027975A3 (en) Novel orally administered pharmaceutical formulations
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
WO2013061004A8 (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
MX2021010046A (en) A new therapeutical composition containing apomorphine as active ingredient.
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
MX2015001917A (en) Pharmaceutical compositions of memantine.
WO2011121607A3 (en) Rasagiline and its pharmaceutically acceptable salts
TN2014000046A1 (en) Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
UA117154C2 (en) S1p3 antagonists
MX2012001691A (en) Orally disintegrating compositions of linaclotide.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11726503

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11726503

Country of ref document: EP

Kind code of ref document: A2